RxSight, a commercial-stage provider of post-cataract intraocular lens platform, announced terms for its IPO on Monday.
The Aliso Viejo, CA-based company plans to raise $125 million by offering 7.4 million shares at a price range of $16 to $18. At the midpoint of the proposed range, RxSight would command a fully diluted market value of $477 million.
RxSight markets its RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens and the RxSight Light Delivery Device, to offers the first and only commercially available intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.
RxSight was founded in 1997 and booked $15 million in sales for the 12 months ended March 31, 2021. It plans to list on the Nasdaq under the symbol RXST. J.P. Morgan, BofA Securities, SVB Leerink, Wells Fargo Securities, and BTIG are the joint bookrunners on the deal. It is expected to price during the week of July 26, 2021.
